Dermatofibrosarcoma Protuberans.
Acosta AE, Vélez CS.
Curr Treat Options Oncol. 2017 Aug 10;18(9):56. doi: 10.1007/s11864-017-0498-5.
Chalazion treatment.
Unal M.
Orbit. 2008;27(6):397-8. doi: 10.1080/01676830802623174.
Tumour microenvironment programming by an RNA-RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma.
Wu L, Zhao Z, Shin YJ, Yin Y, Raju A, Vaiyapuri TS, Idzham K, Son M, Lee Y, Sa JK, Chua JYH, Unal B, Zhai Y, Fan W, Huang L, Hu H, Gunaratne J, Nam DH, Jiang T, Tergaonkar V.
Nat Cell Biol. 2024 Jun;26(6):1003-1018. doi: 10.1038/s41556-024-01428-5. Epub 2024 Jun 10.
Interventricular septal lipoma.
Açar B, Ünal S, Aladağ P, Ertem AG, Ercan K.
Turk Kardiyol Dern Ars. 2017 Dec;45(8):770. doi: 10.5543/tkda.2017.80195.
Ring-Enhancing Lesions-Differentiation with MRI.
Peker E, Ünal S, Uludağ SB, Zorlu NSY.
Br J Hosp Med (Lond). 2024 Oct 30;85(10):1-20. doi: 10.12968/hmed.2024.0195. Epub 2024 Oct 29.
Reactivation of telomerase in cancer.
Akincilar SC, Unal B, Tergaonkar V.
Cell Mol Life Sci. 2016 Apr;73(8):1659-70. doi: 10.1007/s00018-016-2146-9. Epub 2016 Feb 4.
Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management.
Hansen SB, Unal B, Kuzu OF, Saatcioglu F.
Theranostics. 2024 Oct 21;14(18):6913-6934. doi: 10.7150/thno.100555. eCollection 2024.
Nivolumab for pediatric malignant peritoneal mesothelioma.
Yaman Ortaköylü M, İncesoy Özdemir S, Dinçaslan H, Taçyıldız N, Ünal AE, Soydal Ç, Fitöz ÖS, Ünal E.
Pediatr Blood Cancer. 2023 Feb;70(2):e29892. doi: 10.1002/pbc.29892. Epub 2022 Jul 19.
Sclerosing Extramedullary Hematopoietic Tumor.
Deniz K, Kahriman G, Koçyiğit İ, Ökten T, Ünal A.
Turk J Haematol. 2018 Aug 3;35(3):209-210. doi: 10.4274/tjh.2017.0438. Epub 2018 Feb 2.
Venous Invasion in Gastric Cancer.
Ünal E, Karcaaltincaba M.
AJR Am J Roentgenol. 2020 Jan;214(1):W67. doi: 10.2214/AJR.19.21875.
